Cited by 1,627PI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Open access

Berns, Katrien, Horlings, Hugo M., Hennessy, Bryan T., Madiredjo, Mandy, Hijmans, E. Marielle, Beelen, Karin, Linn, Sabine C., Gonzalez-Angulo, Ana Maria, Stemke-Hale, Katherine, Hauptmann, Michael, Beijersbergen, Roderick L., Mills, Gordon B., van de Vijver, Marc J., Bernards, René·2007·Cancer Cell

DOI 10.1016/j.ccr.2007.08.030

Open this paper in CoChat — free account Open PDF

Abstract

A large-scale RNA interference screen to discover genes involved in trastuzumab resistance in breast cancer identified only PTEN as a modulator of drug sensitivity. Oncogenic mutants of PIK3CA (activator of the same pathway and frequently mutated in breast cancer) also conferred resistance to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA mutations or low PTEN expression, was associated with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone. Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2007.08.030

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Flagged first, then by citations

Show all 22 references

2 of the 22 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 1,001

Preclinical development of molecular-targeted agents for cancer
Ocaña, A., Pandiella, A., Siu, L. L., & Tannock, I. F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.194 · Cited by 161
Status of PI3K inhibition and biomarker development in cancer therapeutics
Markman, B., Atzori, F., Pérez-García, J. M., Tabernero, J. M., & Baselga, J. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 160
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
Faratian, D., Goltsov, A., Lebedeva, G., Sorokin, A., Moodie, S., Mullen, P., Kay, C., Um, I. H., Langdon, S. P., Goryanin, I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0777 · Cited by 158
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Sangai, T., Akçakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.-A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1141 · Cited by 158
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
García-García, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzmán, M., Grueso, J., Aura, C. M., Pérez-García, J. M., Jessen, K., Liu, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2750 · Cited by 158
Epithelial-mesenchymal transition and drug resistance in breast cancer (Review)
Huang, J., Li, H., & Ren, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3084 · Cited by 150
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
Zardavas, D., Phillips, W. A., & Loi, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3605 · Cited by 161
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt, J., Rozeboom, B. J., Dey, N., & De, P. K. (2020) · PubMed Central · Cited by 151
Current approaches and future directions in the treatment of HER2-positive breast cancer
Hurvitz, S. A., Hu, Y., O’Brien, N. A., & Finn, R. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 151
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
Fumagalli, D., Venet, D., Ignatiadis, M., Azim, H. A., Maetens, M., Rothé, F., Salgado, R., Bradbury, I., Pusztai, L., Harbeck, N., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3824 · Cited by 151
ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
Stern, D. F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9083-7 · Cited by 150
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest, R. A., Lapi, S. E., Oyama, R., Bose, R., Tabchy, A. B., Marquez-Nostra, B. V., Bartels, J. L., Wright, B. D., Frye, J., Frye, S. A., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0951-z · Cited by 149
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 151
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
Loi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Piccart, M. J., Joensuu, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt121 · Cited by 147
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 148
Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases
Shah, N., Mohammad, A. S., Saralkar, P. A., Sprowls, S. A., Vickers, S. D., John, D. Q., Tallman, R. M., Lucke-Wold, B. P., Jarrell, K. L., Pinti, M. V., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.021 · Cited by 149
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
Liu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16359 · Cited by 120
Treatment of HER2-overexpressing breast cancer
Baselga, J. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq421 · Cited by 146
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 149
A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway
Mullenders, J., Fabius, A. W. M., Madiredjo, M., Bernards, R., & Beijersbergen, R. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004798 · Cited by 146
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 150
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients
Oshiro, C., Kagara, N., Naoi, Y., Shimoda, M., Shimomura, A., Maruyama, N., Shimazu, K., Kim, S. J., & Noguchi, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3322-6 · Cited by 145
Difluorinated-Curcumin (CDF) Restores PTEN Expression in Colon Cancer Cells by Down-Regulating miR-21
Roy, S., Yu, Y., Padhyé, S., Sarkar, F. H., & Majumdar, A. P. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068543 · Cited by 146
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141
MYC Is a Major Determinant of Mitotic Cell Fate
Topham, C. H., Tighe, A., Ly, P., Bennett, A., Sloss, O., Nelson, L., Ridgway, R. A., Huels, D. J., Littler, S., Schandl, C., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.001 · Cited by 144
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Miller, T. W., & Hosford, S. R. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 146
The Role of Mir-148a in Cancer
Li, Y., Deng, X., Zeng, X., & Peng, X. (2016) · Journal of Cancer · doi:10.7150/jca.14616 · Cited by 141
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
Zardavas, D., Marvelde, L. T., Milne, R. L., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E. D., Papaxoinis, G., Joensuu, H., Moynahan, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8301 · Cited by 148
Dissecting the biological heterogeneity of HER2-positive breast cancer
Schettini, F., & Prat, A. (2021) · The Breast · doi:10.1016/j.breast.2021.07.019 · Cited by 154
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
Liang, K., Esteva, F. J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.-Y., Li, Y., Li, X., Chen, C.-T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.025 · Cited by 139
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review)
Libra, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1312 · Cited by 142
Targeted Therapy for Breast Cancer
Mohamed, A., Krajewski, K., Çakar, B., & Ma, C. X. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.005 · Cited by 149
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
Stern, H. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3001539 · Cited by 137
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 135
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Jérusalem, G., Fasolo, A., Dieras, V. C., Cardoso, F., Bergh, J. C. S., Vittori, L., Zhang, Y., Massacesi, C., Sahmoud, T., & Gianni, L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1260-x · Cited by 137
Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
McAuliffe, P. F., Meric‐Bernstam, F., Mills, G. B., & Gonzalez-Angulo, A. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.013 · Cited by 136
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Jensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 135
Anti-HER2 vaccines: new prospects for breast cancer therapy
Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., & Navarro‐Teulon, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0869-2 · Cited by 134
Current technologies for HER2 testing in breast cancer
Moelans, C. B., de Weger, R. A., van der Wall, E., & van Diest, P. J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.12.005 · Cited by 132
Calcium Entry through TRPV1: A Potential Target for the Regulation of Proliferation and Apoptosis in Cancerous and Healthy Cells
Zhai, K., Líšková, A., Kubatka, P., & Büsselberg, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114177 · Cited by 137
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 135
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Saura, C., Bendell, J. C., Jérusalem, G., Su, S., Ru, Q. C., Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1070 · Cited by 137
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Nielsen, D. L., Andersson, M., & Kamby, C. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.003 · Cited by 134
microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling
Lee, K. M., Choi, E. J., & Kim, I. A. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.050 · Cited by 133
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Kim, J., Fox, C., Peng, S., Pusung, M., Pectasides, E., Matthée, E., Hong, Y. S., Do, I., Jang, J., Thorner, A. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75200 · Cited by 133
Cancer biomarker discovery: Current status and future perspectives
Mäbert, K., Cojoc, M., Peitzsch, C., Kurth, I., Souchelnytskyi, S., & Dubrovska, A. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.892229 · Cited by 137
Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance
Gooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 141
Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V. M., Dugger, T. C., Granja, N. D. M., Narasanna, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1665 · Cited by 130
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
Espelin, C. W., Leonard, S. C., Geretti, E., Wickham, T. J., & Hendriks, B. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1518 · Cited by 132
HER2-positive breast cancer: Current and new therapeutic strategies
Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 132
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Huober, J., Barrios, C. H., Niikura, N., Jarząb, M., Chang, Y., Huggins-Puhalla, S. L., Pedrini, J. L., Zhukova, L., Graupner, V., Eiger, D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02772 · Cited by 134
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
Molecular Characterization of Apocrine Salivary Duct Carcinoma
Chiosea, S. I., Williams, L., Griffith, C. C., Thompson, L. D. �., Weinreb, I., Bauman, J. E., Luvison, A., Roy, S., Seethala, R. R., & Nikiforova, M. N. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000410 · Cited by 129
Increased autophagy blocks HER2-mediated breast tumorigenesis
Vega-Rubín-de-Celis, S., Zou, Z., Fernández, Á. F., Ci, B., Kim, M., Xiao, G., Xie, Y., & Levine, B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717800115 · Cited by 131
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3 -Mutant Cancer
Herrera-Abreu, M. T., Pearson, A., Campbell, J., Shnyder, S. D., Knowles, M. A., Ashworth, A., & Turner, N. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0569 · Cited by 131
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xu, X., Angelis, C. D., Burke, K. A., Nardone, A., Hu, H., Qin, L., Veeraraghavan, J., Sethunath, V., Heiser, L. M., Wang, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2191 · Cited by 126
LncRNA NKILA suppresses TGF‐β‐induced epithelial–mesenchymal transition by blocking NF‐κB signaling in breast cancer
Wu, W., Chen, F., Cui, X., Yang, L., Chen, J., Zhao, J., Huang, D., Liu, J., Yang, L., Zeng, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31605 · Cited by 127
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
The Biological Role of PI3K Pathway in Lung Cancer
Sarris, E., Saif, M. W., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 128
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 141
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Yao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2814 · Cited by 125
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond
García‐Alonso, S., Ocaña, A., & Pandiella, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.010 · Cited by 129
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Norell, H., Poschke, I. C., Charo, J., Wei, W. Z., Erskine, C. L., Piechocki, M. P., Knutson, K. L., Bergh, J. C. S., Lidbrink, E. K., & Kiessling, R. W. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-53 · Cited by 127
The therapeutic potential of mTOR inhibitors in breast cancer
Steelman, L. S., Martelli, A. M., Cocco, L., Libra, M., Nicoletti, F., Abrams, S. L., & McCubrey, J. A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12958 · Cited by 124
The role of the miR‐148/‐152 family in physiology and disease
Friedrich, M., Pracht, K., Mashreghi, M., Jäck, H., Radbruch, A., & Seliger, B. (2017) · European Journal of Immunology · doi:10.1002/eji.201747132 · Cited by 126
The Breast Cancer Stem Cells Traits and Drug Resistance
Zheng, Q., Zhang, M., Zhou, F., Zhang, L., & Meng, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.599965 · Cited by 133
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 125
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 125
Molecular Target Class Is Predictive of In vitro Response Profile
Greshock, J. D., Bachman, K. E., Degenhardt, Y., Jing, J., Wen, Y. H., Eastman, S. D., McNeil, E., Moy, C. H., Wegrzyn, R. J., Auger, K. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3788 · Cited by 124
Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment
Islam, F., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.04.018 · Cited by 132
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 121
Vorinostat (SAHA) and Breast Cancer: An Overview
Wawruszak, A., Borkiewicz, L., Okoń, E., Kukuła‐Koch, W., Afshan, S., & Hałasa, M. (2021) · Cancers · doi:10.3390/cancers13184700 · Cited by 124
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Derakhshani, A., Rezaei, Z., Safarpour, H., Sabri, M., Mir, A., Sanati, M. A., Vahidian, F., Moghadam, A. G., Aghadoukht, A., Hajiasgharzadeh, K., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29216 · Cited by 128
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
O’Brien, N. A., McDonald, K., Luo, T., von Euw, E., Kalous, O., Conklin, D. F., Hurvitz, S. A., di Tomaso, E., Schnell, C., Linnartz, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2769 · Cited by 122
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 119
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Chang, C. A., Jen, J., Jiang, S., Sayad, A., Mer, A. S., Brown, K. R., Nixon, A. M. L., Dhabaria, A., Tang, K. H., Venet, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1265 · Cited by 119
Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer
Johnstone, C. N., Chand, A. L., Putoczki, T. L., & Ernst, M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.015 · Cited by 122
The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination
Huang, G., Xiang, Z., Wu, H., He, Q., Dou, R., Lin, Z., Yang, C., Huang, S., Song, J., Di, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69454 · Cited by 118
Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis
McCubrey, J. A., Abrams, S. L., Fitzgerald, T. L., Cocco, L., Martelli, A. M., Montalto, G., Cervello, M., Scalisi, A., Candido, S., Libra, M., et al. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.016 · Cited by 118
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection
Li, H., Wawrose, J. S., Gooding, W. E., Garraway, L. A., Lui, V. W. Y., Peyser, N. D., & Grandis, J. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0396 · Cited by 116
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer
Hu, X., Ma, Z., Xu, B., Li, S., Yao, Z., Liang, B., Wang, J., Liao, W., Li, L., Wang, C., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12459 · Cited by 116
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 113
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Brown, K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 115
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Chen, F. L., Xia, W., & Spector, N. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0581 · Cited by 114
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L. Y., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2014) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 110
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 112
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
Köninki, K., Barok, M., Tanner, M., Staff, S. M., Pitkänen, J., Hemmilä, P., Ilvesaro, J. M., & Isola, J. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.002 · Cited by 112
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
Pogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 111
Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
Kim, H.-P., Han, S.-W., Song, S., Jeong, E.-G., Lee, M.-Y., Hwang, D., Im, S., Bang, Y.-J., & Kim, T.-Y. (2013) · Oncogene · doi:10.1038/onc.2013.285 · Cited by 110
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Lauring, J. D., Park, B. H., & Wolff, A. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0086 · Cited by 114
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
Guarneri, V., Dieci, M. V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S. R., Tagliafico, E., Bicciato, S., Generali, D., Cagossi, K., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0138 · Cited by 109
Tumour suppressor genes in chemotherapeutic drug response
Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 110
Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival
Baker, A. T., Wyatt, D. L., Bocchetta, M., Li, J., Filipović, A., Green, A. R., Peiffer, D. S., Fuqua, S. A. W., Miele, L., Albain, K. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0251-y · Cited by 108
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Alqahtani, A., Ayesh, H., & Halawani, H. (2019) · Cancers · doi:10.3390/cancers12010093 · Cited by 113
Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
Xue, Q., Hopkins, B. D., Perruzzi, C. A., Udayakumar, D., Sherris, D., & Benjamin, L. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2058 · Cited by 109
Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance
van Agthoven, T., Sieuwerts, A. M., Gelder, M. E. M., Look, M. P., Smid, M., Veldscholte, J., Sleijfer, S., Foekens, J. A., & Dorssers, L. C. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1462 · Cited by 108
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 108
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
Raina, D. B., Uchida, Y., Kharbanda, A., Rajabi, H. N., Panchamoorthy, G., Jin, C., Kharbanda, S. M., Scaltriti, M., Baselga, J. M., & Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2013.308 · Cited by 108

Authors: Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., Beijersbergen, R. L., Mills, G. B., van de Vijver, M. J., & Bernards, R.
Affiliations: The Netherlands Cancer Institute (NL)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Bernards, René
ORCID: Berns, Katrien
Horlings, Hugo M.
Hennessy, Bryan T.
Hijmans, E. Marielle
Beelen, Karin
Linn, Sabine C.
Gonzalez-Angulo, Ana Maria
Hauptmann, Michael
Beijersbergen, Roderick L.
Mills, Gordon B.
Bernards, René
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2007-10
Volume: 12
Issue: 4
Pages: 395-402
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2007.08.030
OpenAlex: W2020372547
Cited by: 1,627
References: 22
Citations by year: 2026: 26 · 2025: 44 · 2024: 33 · 2023: 81 · 2022: 69 · 2021: 54 · 2020: 63 · 2019: 70 · 2018: 88 · 2017: 74 · 2016: 102 · 2015: 116 · 2014: 118 · 2013: 144 · 2012: 123
FWCI: 37.98
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2116 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: trastuzumab resistance, breast cancer, PI3K signaling, PTEN, PIK3CA mutation, RNAi screen, drug sensitivity, prognostic factors, HER2-positive breast cancer, treatment response prediction
MeSH terms: Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Transduction, Genetic, Biomarkers, Tumor, Cohort Studies, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease Progression, Patient Selection, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, PTEN Phosphohydrolase, Kaplan-Meier Estimate, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks